# SARS-CoV-2 Genomic Surveillance in Brazil

Jorge Kalil, MD, PhD, *Dr hc*, FRCP (LON)
Instituto Todos pela Saúde
Faculdade de Medicina da USP

# Real-time virus genome sequencing: maximizing public health impact



**Effective genomic surveillance requires** high quality samples and metadata **and** substantial investment in terms of staff, equipment, reagents, bioinformatic infrastructure, **and** effective collaboration between scientific community and stakeholders

# Untargeted sequencing

Pathogen identification, understand origins of viral outbreaks

RequireGoal

Metagenomics human and non-human samples


# Targeted sequencing GACAACCAAGTAGG TGCAACCAAICAGG CGCTACCAAICAGG

Design of diagnostics, therapeutics, phenotypic changes (e.g., Alpha, Omicron)

Targeted sequencing of  $\Delta 69-70$ , extensive experimental work

Investigate transmission clusters & complement epi (e.g., outbreaks in hospitals, travelers)


Non-random, dense cluster & community sequencing




Large-scale patterns, drivers and assess detection (e.g., *R*, *pop size*, *dispersal patterns*)

Random population (representativity) sequencing

Disparities in SARS-CoV-2global genomic surveillance



Turn around time and number of sequences are important to detect new variants in real time



## ITpS (Instituto Todos pela Saúde)


**Instituto Todos pela Saúde (ITpS)** is a non-profit organization created in Feb 2021.

**Objective** – Collaborate in the development of an epidemiological surveillance system to prepare Brazil to face future outbreaks.

Articulate networks to obtain relevant scientific information to help the country in public health decision-making.



# Evolution of the number of SARS-CoV-2 genomes in Brazil




- Over 183,000 complete genome sequences (15 Oct'22)
- Over 34.6 million reported cases ( 0.53% sequenced)
- 54 days from sample collection to GISAID deposition

# Epidemic virus: Number of fulllength genome from Brazil


Virus	No. Brazil Genomes in GenBank or GiSAID	
Yellow fever	195	
Dengue 1-4	281	
St. Louis encephalitis virus	1	
West Nile	5	
Zika	76	
Mayaro virus	24	
Venezuelan equine encephalitis virus	0	
Chikungunya	78	
Influenza	1182	

# Heterogeneity in sequencing platforms used



#### (1) Brazil-UK CADDE Research Collaboration







#### **Evolution and epidemic spread of SARS-CoV-2 in Brazil**

Darlan S. Candido<sup>1,2</sup>\*, Ingra M. Claro<sup>2,3</sup>\*, Jaqueline G. de Jesus<sup>2,3</sup>\*, William M. Souza<sup>4</sup>\*, Filipe R. R. Moreira<sup>5</sup>\*, Simon Dellicour<sup>6,7</sup>\*, Thomas A. Mellan<sup>8</sup>\*, Louis du Plessis<sup>1</sup>, Rafael H. M. Pereira<sup>9</sup>, Flavia C. S. Sales<sup>2,3</sup>, Erika R. Manuli<sup>2,3</sup>, Julien Thézé<sup>10</sup>, Luiz Almeida<sup>11</sup>, Mariane T. Menezes<sup>5</sup>, Carolina M. Voloch<sup>5</sup>, Marcilio J. Fumagalli<sup>4</sup>, Thaís M. Coletti<sup>2,3</sup>, Camila A. M. da Silva<sup>2,3</sup>. Mariana S. Ramundo<sup>2,3</sup>. Mariene R. Amorim<sup>12</sup>. Henrique H. Hoeltgebaum<sup>13</sup>. Swapnil Mishra<sup>8</sup>, Mandey S. Gill<sup>7</sup>, Luiz M. Carvalho<sup>14</sup>, Lewis F. Buss<sup>2</sup>, Carlos A. Prete Jr. 15. Jordan Ashworth<sup>16</sup>, Helder I. Nakaya<sup>17</sup>, Pedro S. Peixoto<sup>18</sup>, Oliver J. Brady<sup>19,20</sup>, Samuel M. Nicholls<sup>2</sup> Amilcar Tanuri<sup>5</sup>, Átila D. Rossi<sup>5</sup>, Carlos K. V. Braga<sup>9</sup>, Alexandra L. Gerber<sup>11</sup>, Ana Paula de C. Guimarães<sup>11</sup>, Nelson Gaburo Jr.<sup>22</sup>, Cecila Salete Alencar<sup>23</sup>, Alessandro C. S. Ferreira<sup>24</sup>, Cristiano X. Lima<sup>25,26</sup>, José Eduardo Levi27, Celso Granato28, Giulia M. Ferreira29, Ronaldo S. Francisco Jr.11, Fabiana Grania 12,30, Marcia T. Garcia 31, Maria Luiza Moretti 31, Mauricio W. Perroud Jr. 32, Terezinha M. P. P. Castiñeiras<sup>33</sup>, Carolina S. Lazari<sup>34</sup>, Sarah C. Hill<sup>35</sup>, Andreza Aruska de Souza Santos<sup>36</sup> Camila L. Simeoni<sup>12</sup>, Julia Forato<sup>12</sup>, Andrei C. Sposito<sup>37</sup>, Angelica Z. Schreiber<sup>38</sup>, Magnun N. N. Santos<sup>38</sup>, Camila Zolini de Sá<sup>39</sup>, Renan P. Souza<sup>39</sup>, Luciana C. Resende-Moreira<sup>40</sup>, Mauro M. Teixeira<sup>41</sup>, Josy Hubner<sup>42</sup>, Patricia A. F. Leme<sup>43</sup>, Rennan G. Moreira<sup>44</sup>, Maurício L. Nogueira<sup>45</sup>, Brazil-UK Centre for Arbovirus Discovery. Diagnosis, Genomics and Epidemiology (CADDE) Genomic Network, Neil M. Ferguson<sup>8</sup>, Silvia F. Costa<sup>2,3</sup>, José Luiz Proenca-Modena<sup>12</sup>, Ana Tereza R. Vasconcelos<sup>11</sup>, Samir Bhatt<sup>8</sup> Philippe Lemey, Chieh-Hsi Wu46, Andrew Rambaut47, Nick J. Loman21, Renato S. Aguiar39, Oliver G. Pybus<sup>1</sup>, Ester C. Sabino<sup>2,3</sup>†, Nuno Rodrigues Faria<sup>1,2,8</sup>†

#### CORONAVIRUS

#### Three-quarters attack rate of SARS-CoV-2 in the **Brazilian Amazon during a largely** unmitigated epidemic

Lewis F. Buss1\*, Carlos A. Prete Jr.2\*, Claudia M. M. Abrahim3\*, Alfredo Mendrone Jr.4.5\*, Tassila Salomon<sup>6,7</sup>, Cesar de Almeida-Neto<sup>4,5</sup>, Rafael F. O. França<sup>8</sup>, Maria C. Belotti<sup>2</sup>, Maria P. S. S. Carvalho<sup>3</sup>, Allyson G. Costa<sup>3</sup>, Myuki A. E. Crispim<sup>3</sup>, Suzete C. Ferreira<sup>4,5</sup>, Nelson A. Fraiji<sup>3</sup>, Susie Gurzenda<sup>9</sup>, Charles Whittaker<sup>10</sup>, Leonardo T. Kamaura<sup>11</sup>, Pedro L. Takecian<sup>11</sup>, Pedro da Silva Peixoto<sup>11</sup>, Marcio K. Oikawa<sup>12</sup>, Anna S. Nishiya<sup>4,5</sup>, Vanderson Rocha<sup>4,5</sup>, Nanci A. Salles<sup>4</sup>, Andreza Aruska de Souza Santos<sup>13</sup>, Martirene A. da Silva<sup>3</sup>, Brian Custer<sup>14,15</sup>, Kris V. Parag<sup>16</sup>, Manoel Barral-Netto<sup>17</sup>, Moritz U. G. Kraemer<sup>18</sup>, Rafael H. M. Pereira<sup>19</sup>, Oliver G. Pybus<sup>18</sup>. Michael P. Busch<sup>14,15</sup>. Márcia C. Castro<sup>9</sup>. Christopher Dve<sup>18</sup>. Vítor H. Nascimento<sup>2</sup>. Nuno R. Faria 1,16,18 +. Ester C. Sabino 1+

Buss et al., Science 371, 288-292 (2021) 15 January 2021

Science

#### **Genomics and epidemiology of the P.1 SARS-CoV-2** lineage in Manaus, Brazil

Nuno R. Faria<sup>1,2,3,4</sup>\*+, Thomas A. Mellan<sup>1,2</sup>+, Charles Whittaker<sup>1,2</sup>+, Ingra M. Claro<sup>3,5</sup>+, Darlan da S. Candido<sup>3,4</sup>†, Swapnil Mishra<sup>1,2</sup>†, Myuki A. E. Crispim<sup>6,7</sup>, Flavia C. S. Sales<sup>3,5</sup>, Iwona Hawryluk<sup>1,2</sup>, John T. McCrone<sup>8</sup>, Ruben J. G. Hulswit<sup>9</sup>, Lucas A. M. Franco<sup>3,5</sup>, Mariana S. Ramundo<sup>3,5</sup>, Jaqueline G. de Jesus<sup>3,5</sup>, Pamela S. Andrade<sup>10</sup>, Thais M. Coletti<sup>3,5</sup> Giulia M. Ferreira<sup>11</sup>, Camila A. M. Silva<sup>3,5</sup>, Erika R. Manuli<sup>3,5</sup>, Rafael H. M. Pereira<sup>12</sup>, Pedro S. Peixoto<sup>13</sup>, Moritz U. G. Kraemer<sup>4</sup>, Nelson Gaburo Jr.<sup>14</sup>, Cecilia da C. Camilo<sup>14</sup>, Henrique Hoeltgebaum<sup>15</sup>. William M. Souza<sup>16</sup>, Esmenia C. Rocha<sup>3,5</sup>, Leandro M. de Souza<sup>3,5</sup>, Mariana C. de Pinho<sup>3,5</sup>, Leonardo J. T. Araujo<sup>17</sup>, Frederico S. V. Malta<sup>18</sup>, Aline B. de Lima<sup>18</sup>, Joice do P. Silva<sup>18</sup>, Danielle A. G. Zauli<sup>18</sup>, Alessandro C. de S. Ferreira<sup>18</sup>, Ricardo P. Schnekenberg<sup>19</sup>, Daniel J. Laydon<sup>1,2</sup>, Patrick G. T. Walker<sup>1,2</sup>, Hannah M. Schlüter<sup>15</sup>, Ana L. P. dos Santos<sup>20</sup>, Maria S. Vidal<sup>20</sup>, Valentina S. Del Caro<sup>20</sup>, Rosinaldo M. F. Filho<sup>20</sup>, Helem M. dos Santos<sup>20</sup>, Renato S. Aguiar<sup>21</sup>, José L. Proença-Modena<sup>22</sup>, Bruce Nelson<sup>23</sup>, James A. Hay<sup>24,25</sup>, Mélodie Monod<sup>15</sup>, Xenia Miscouridou<sup>15</sup>, Helen Coupland<sup>1,2</sup>, Raphael Sonabend<sup>1,2</sup>, Michaela Vollmer<sup>1,2</sup>, Axel Gandv<sup>15</sup>, Carlos A, Prete Jr.<sup>26</sup> Vitor H. Nascimento<sup>26</sup>, Marc A. Suchard<sup>27</sup>, Thomas A. Bowden<sup>9</sup>, Sergei L. K. Pond<sup>28</sup>, Chieh-Hsi Wu<sup>29</sup>, Oliver Ratmann<sup>15</sup>, Neil M. Ferguson<sup>1,2</sup>, Christopher Dye<sup>4</sup>, Nick J. Loman<sup>30</sup>, Philippe Lemey<sup>31</sup>, Andrew Rambaut<sup>8</sup>, Nelson A. Fraiji<sup>6,32</sup>, Maria do P. S. S. Carvalho<sup>6,33</sup>, Oliver G. Pybus<sup>4,34</sup>‡, Seth Flaxman<sup>15</sup>‡, Samir Bhatt<sup>1,2,35</sup>\*‡, Ester C. Sabino<sup>3,5</sup>\*‡

Faria et al., Science 372, 815-821 (2021) 21 May 2021

Science

#### (2) FioCruz Genomic Network



#### COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence

Felipe Gomes Naveca <sup>1 ⋈</sup>, Valdinete Nascimento¹, Victor Costa de Souza¹, André de Lima Corado¹, Fernanda Nascimento¹, George Silva¹, Ágatha Costa¹, Débora Duarte¹, Karina Pessoa¹, Matilde Mejía¹, Maria Júlia Brandão¹, Michele Jesus², Luciana Gonçalves³, Cristiano Fernandes da Costa³, Vanderson Sampaio <sup>3</sup>, Daniel Barros³, Marineide Silva⁴, Tirza Mattos⁴, Gemilson Pontes⁵, Ligia Abdalla⁶, João Hugo Santosˀ, Ighor Arantes³, Filipe Zimmer Dezordi⁶, Marilda Mendonça Siqueira¹o, Gabriel Luz Wallau⁶, Paola Cristina Resende <sup>1</sup>0, Edson Delatorre <sup>1</sup>1, Tiago Gräf¹² and Gonzalo Bello <sup>8</sup> <sup>8</sup>

VOL 27 | JULY 2021 | 1230-1238 | www.nature.com/naturemedicine





### (3) CoronaOmica Network





Virus Evolution, 2021, **7(2)**, 1–12

DOI: https://doi.org/10.1093/ve/veab087

Advance access publication date: 1 October 2021

#### Epidemiological dynamics of SARS-CoV-2 VOC Gamma in Rio de Janeiro, Brazil

Filipe Romero Rebello Moreira, <sup>1,1,5</sup> Mirela D'arc, <sup>2,1</sup> Diana Mariani, <sup>1</sup> Alice Laschuk Herlinger, <sup>1</sup> Francine Bittencourt Schiffler, <sup>2</sup> Aftila Duque Rossi, <sup>1</sup> Isabela de Carvalho Leitão, <sup>2</sup> Thamiris dos Santos Miranda, <sup>3</sup> Matheus Augusto Calvano Cosentino, <sup>3</sup> Marcelo Calado de Paula Törres, <sup>3</sup> Raísa Mirella dos Santos Cunha da Costa, <sup>3</sup> Cássia Cristina Alves Gongalves, <sup>3</sup> Debora Souza Faffe, <sup>3</sup> Raísal Mello Galliez, <sup>4</sup> Orlando da Costa Ferreira Junior, <sup>3</sup> Renato Santana Aguiar, <sup>3,6</sup> André Felipe Andrade dos Santos, <sup>2</sup> Carolina Moreira Voloch, <sup>3,1</sup> Terezinha Marta Pereira Pinto Castiñeiras, <sup>3,4</sup> and Amilcar Tanuri<sup>1,6</sup> on behalf of the COVID-19-UFRJ Workgroup



### (4) Butantan Network




### Genomic epidemiology of the SARS-CoV-2 epidemic in Brazil



The high numbers of COVID-19 cases and deaths in Brazil have made Latin America an epicentre of the pandemic. SARS-CoV-2 established sustained transmission in Brazil early in the pandemic, but important gaps remain in our understanding of virus transmission dynamics at a national scale. We use 17,135 near-complete genomes sampled from 27 Brazilian states and bordering country Paraguay. From March to November 2020, we detected co-circulation of multiple viral lineages that were linked to multiple importations (predominantly from Europe). After November 2020, we detected large, local transmission clusters within the country. In the absence of effective restriction measures, the epidemic progressed, and in January 2021 there was emergence and onward spread, both within and abroad, of variants of concern and variants under monitoring, including Gamma (P.1) and Zeta (P.2). We also characterized a genomic overview of the epidemic in Paraguay and detected evidence of importation of SARS-CoV-2 ancestor lineages and variants of concern from Brazil. Our findings show that genomic surveillance in Brazil enabled assessment of the real-time spread of emerging SARS-CoV-2 variants.




#### Weekly Reports starting in May 2021




Coordinators: Dimas Covas | Funding: Secretary State São Paulo Brazil


## (5) Seq-BR – Magalu & Mulheres do Brasil

- Designed in May 2021
- First Phase: Training between March and September 2022
- Second Phase (ongoing): 100 seq/month/Brazilian State Capital performed locally
- Third Phase: wastewater sewage genomic surveillance



# SEQVER Sequenciamento em rede





### (6) Genov Network



• Convenient residual diagnostic samples from large private laboratory network

Brazilian Region	No. (GISAID, 15 Sep 2022)	% cases
SOUTH	2,912	16.8
SOUTHEAST	3,463	20.0
MID-WEST	2,461	14.2
NORTHEAST	1,884	10.9
NORTH	147	0.8
SÃO PAULO CITY	3,716	21.4
RIO DE JANEIRO CITY	2,763	15.9
TOTAL	17,346	100

## **Dynamics of SARS-CoV-2 Variants of Concern in Brazil, Early 2021**

José Eduardo Levi <sup>1,2\*</sup>, Cristina Mendes Oliveira <sup>1</sup>, Bianca Della Croce <sup>1</sup>, Paulo Telles <sup>1,3</sup>, Annelise Correa Wengerkievicz Lopes <sup>1</sup>, Camila Malta Romano <sup>2,4</sup>, Diego Bezerra Lira <sup>1</sup>, Anna Claudia Mello de Resende <sup>1</sup>, Flávia Paiva Lopes <sup>1</sup>, André Arroyo Ruiz <sup>1</sup> and Gustavo Campana <sup>1</sup>



Website: <a href="https://dasa.com.br/genov/">https://dasa.com.br/genov/</a> | Coordinators: Eduardo Levi | Funding: DASA Laboratories

## (7) ITpS (Instituto Todos pela Saúde)




How to improve turn around time?

Data from private laboratories

Turn around time: 7 days

Data from ThermoFischer PCR: SGTFvs SGTP

Data from all results: PCR+ rate




## ITpS (Instituto Todos pela Saúde)





Monitoramento da variante Ômicron

(de 01/05/2022 a 29/10/2022)










Positividade de testes para COVID-19 (de 01/05/2022 a 29/10/2022)







#### Conclusions

- Brazil has dramatically expanded the capacity to perform SARS-CoV-2 full-length genome sequencing across the country through state and private funding initiatives.
- Genomic diversity of other epidemic viruses remains poorly understood
- Median: 54 days date of collection to submission to GISAID.
- Still a long delay between sample collection, sequence and information to the public for SARS-CoV-2, but even longer for other viruses.
- Need to organize the several initiatives to improve cost/effectiveness and sustainability of targeted and untargeted (metagenomic) virus sequencing.